Human α-Defensin 51–9 and Human β-Defensin 2 Improve Metabolic Parameters and Gut Barrier Function in Mice Fed a Western-Style Diet
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241813878 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Louisa Filipe Rosa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Nutritional Medicine, University of Hohenheim, Fruwirthstr. 12, 70599 Stuttgart, Germany. Hauptthemen laut MEDLINE: alpha-Defensins, beta-Defensins, Diet, Western, Intestinal Mucosa. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Obesity and metabolic comorbidities are associated with gut permeability. While high-fructose and Western-style diet (WSD) disrupt intestinal barrier function, oral administration of human α-defensin 5 (HD5) and β-defensin 2 (hBD2) is believed to improve intestinal integrity and metabolic disorders. Eighty-four male C57BL/6J mice were fed a WSD or a control diet (CD) ± fructose (F) for 18 weeks. In week 13, mice were randomly divided into three intervention groups, receiving defensin fragment HD51–9, full-length hBD2, or bovine serum albumin (BSA)-control for six weeks. Subsequently, parameters of hepatic steatosis, glucose metabolism, and gut barrier function were assessed. WSDF increased body weight and hepatic steatosis (p < 0.01) compared to CD-fed mice, whereas peptide intervention decreased liver fat (p < 0.05) and number of hepatic lipid droplets (p < 0.01) compared to BSA-control. In addition, both peptides attenuated glucose intolerance by reducing blood glucose curves in WSDF-fed mice. Evaluation of gut barrier function revealed that HD51–9 and hBD2 improve intestinal integrity by upregulating tight junction and mucin expression. Moreover, peptide treatment restored ileal host defense peptides (HDP) expression, likely by modulating the Wnt, Myd88, p38, and Jak/STAT pathways. These findings strongly suggest that α- and β-defensin treatment improve hepatic steatosis, glucose metabolism, and gut barrier function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Nutritional Medicine, University of Hohenheim, Fruwirthstr. 12, 70599 Stuttgart, Germany.
- Department of Medicine 1, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
- Deutsches Zentrum Immuntherapie (DZI), Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
- Department of Internal Medicine I, University Hospital Tübingen, 72016 Tübingen, Germany.
- Defensin Therapeutics, 2200 Copenhagen, Denmark.
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 1353 Copenhagen, Denmark.
ORCID-Profile: Louisa Filipe Rosa, Julia Beisner, Benjamin A H Jensen, Stephan C Bischoff
Zitieren
APA
Filipe Rosa, L., Rings, A., Stolzer, I., Koeninger, L., Wehkamp, J., Beisner, J., Günther, C., Nordkild, P., Jensen, B. A. H., & Bischoff, S. C. (2023). Human α-Defensin 51–9 and Human β-Defensin 2 Improve Metabolic Parameters and Gut Barrier Function in Mice Fed a Western-Style Diet. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241813878
Vancouver
Filipe Rosa L, Rings A, Stolzer I, Koeninger L, Wehkamp J, Beisner J, et al. Human α-Defensin 51–9 and Human β-Defensin 2 Improve Metabolic Parameters and Gut Barrier Function in Mice Fed a Western-Style Diet. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241813878
BibTeX
@article{FilipeRosa2023,
author = {Filipe Rosa, Louisa and Rings, Andreas and Stolzer, Iris and Koeninger, Louis and Wehkamp, Jan and Beisner, Julia and Günther, Claudia and Nordkild, Peter and Jensen, Benjamin A H and Bischoff, Stephan C},
title = {Human α-Defensin 51–9 and Human β-Defensin 2 Improve Metabolic Parameters and Gut Barrier Function in Mice Fed a Western-Style Diet},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241813878}
}
EUVIMED